News & Updates
Filter by Specialty:
Oteseconazole bests fluconazole for vaginal yeast infections
Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.
Oteseconazole bests fluconazole for vaginal yeast infections
05 Oct 2021
Vedolizumab yields sustained improvements in fistulizing Crohn’s disease
Intravenous dosing regimens of vedolizumab appear to favourably alter outcomes in patients with fistulizing Crohn’s disease, according to data from the phase IV ENTERPRISE trial.
Vedolizumab yields sustained improvements in fistulizing Crohn’s disease
05 Oct 2021
COVID-19 in childhood cancer patients: What are the risk factors?
A large international database study has shown that children and adolescents with cancer have an elevated risk of severe or critical disease if infected with COVID-19. Furthermore, about half the patients receiving cancer therapy experienced modifications to their treatment regimens.
COVID-19 in childhood cancer patients: What are the risk factors?
04 Oct 2021
Varenicline plus naltrexone may aid in smoking cessation, drinking reduction
Varenicline alone is an adequate therapy for smoking cessation in heavy-drinking smokers, but combining it with naltrexone may provide benefits in terms of drinking outcomes, particularly during the 12-week period of active medication treatment, suggests a study.
Varenicline plus naltrexone may aid in smoking cessation, drinking reduction
04 Oct 2021
Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis
Treatment with azathioprine helps prevent relapse of autoimmune pancreatitis, according to the results of a systematic review and meta-analysis.
